Cancer Chemotherapy and Pharmacology

, Volume 83, Issue 3, pp 419–424 | Cite as

Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205)

  • Yusuke SuwaEmail author
  • Jun Watanabe
  • Mitsuyoshi Ota
  • Shinsuke Suzuki
  • Hirokazu Suwa
  • Kazuteru Watanabe
  • Shuji Saito
  • Koutaro Nagamine
  • Masashi Momiyama
  • Atsushi Ishibe
  • Yusuke Saigusa
  • Takeharu Yamanaka
  • Itaru Endo
Original Article



Capeox is widely used as an adjuvant chemotherapy regimen of colorectal cancer that does not require central vein catheter insertion. However, oxaliplatin-related vascular pain with peripheral administration is a major adverse event. We assessed the preventive effect of Celecoxib on oxaliplatin-related vascular pain.


A multicenter study of the Yokohama Clinical Oncology Group (YCOG) in Japan. This study was an open label, randomized non-comparative phase II study between Capeox without Celecoxib (C+ Group) and with it (C− group). The primary endpoint was the appearance frequency of grade ≥ 2 vascular pain according to the Verbal Rating Scale (VRS).


Between October 2012 and February 2014, 81 patients were recruited to this study and randomly divided into 2 groups: 38 patients in the C− group and 39 patients in the C+ group. Four cases were excluded at the analysis stage because they had not received the allocated intervention. The rate of grade ≥ 2 vascular pain was 55.3% in the C− group and 53.8% in the C+ group (p = 1.000).


Celecoxib was unable to prevent oxaliplatin-related vascular pain in this study. However, it may be able to decrease the vascular pain that patients already have.


Oxaliplatin Vascular pain Celecoxib Colon cancer Capeox 



I wish to thank all of the doctors, pharmacists, and nurses concerned with this trial.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351CrossRefPubMedGoogle Scholar
  2. 2.
    Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204CrossRefPubMedGoogle Scholar
  3. 3.
    André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116CrossRefPubMedGoogle Scholar
  4. 4.
    Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29(28):3768CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll H-J (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29(11):1465–1471CrossRefPubMedGoogle Scholar
  6. 6.
    Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, Tanaka T, Hirata K, Tamura K, Yamashita Y (2015) Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. Int J Clin Oncol 20(2):332–337. CrossRefPubMedGoogle Scholar
  7. 7.
    Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J (2013) Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther 37(3):346–354. CrossRefPubMedGoogle Scholar
  8. 8.
    Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884. CrossRefPubMedGoogle Scholar
  9. 9.
    Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET (2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2(4):310–321. CrossRefGoogle Scholar
  10. 10.
    Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885–895. CrossRefPubMedGoogle Scholar
  11. 11.
    Reddy BS, Rao CV (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 21(2):155–164CrossRefPubMedGoogle Scholar
  12. 12.
    Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F (2016) The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-kappaB genes expression. Cell Mol Biol (Noisy-le-grand) 62(2):68–74Google Scholar
  13. 13.
    Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73(9):1318–1329. CrossRefPubMedGoogle Scholar
  14. 14.
    Egashira I, Takahashi-Yanaga F, Nishida R, Arioka M, Igawa K, Tomooka K, Nakatsu Y, Tsuzuki T, Nakabeppu Y, Kitazono T, Sasaguri T (2017) Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/beta-catenin signaling pathway. Cancer Sci 108(1):108–115. CrossRefPubMedGoogle Scholar
  15. 15.
    Ohnhaus EE, Adler R (1975) Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1(4):379–384CrossRefPubMedGoogle Scholar
  16. 16.
    Chvetzoff G, Tannock IF (2003) Placebo effects in oncology. J Natl Cancer Inst 95(1):19–29CrossRefPubMedGoogle Scholar
  17. 17.
    Beijers AJ, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007. CrossRefPubMedGoogle Scholar
  18. 18.
    Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, Yamauchi K, Honda Y, Komori K, Tsujinaka T (2011) Etiology and management of venous pain during intravenous administration of oxaliplatin. Jpn J Cancer Chemother 38(3):411–414Google Scholar
  19. 19.
    Cathomas R, Koberle D, Ruhstaller T, Mayer G, Rass A, Mey U, von Moos R (2010) Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18(10):1263–1270. CrossRefPubMedGoogle Scholar
  20. 20.
    Miyajima R, Kawazoe H, Tsuneoka K, Fujiwara M, Kojima Y, Yakushijin Y (2013) Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain. Gan To Kagaku Ryoho 40(4):537–540PubMedGoogle Scholar
  21. 21.
    Okada Y, Sayoko Kajiume RNC, Takoko Taniguchi RNC, BCOPS SK, BCOPS YO (2013) Coadministration of 5% glucose solution and dexamethasone and oxaliplatin-related vascular pain grade: a case study. Clin J Oncol Nurs 17(5):554CrossRefPubMedGoogle Scholar
  22. 22.
    Yoshida Y, Hoshino S, Aisu N, Shiwaku H, Beppu R, Tanimura S, Yamashita Y (2012) Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res 2(2):132–141CrossRefGoogle Scholar
  23. 23.
    Shiotsuka Y, Uebuchi M, Hamada S, Morita N, Moriyama A, Yamashita M, Ichikawa Y, Fujii H, Matsuo A, Kuhara H, Ikuta Y, Ikeshima S, Kuramoto M, Fujii K, Shimada S (2012) Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone. Gan To Kagaku Ryoho 39(10):1583–1586PubMedGoogle Scholar
  24. 24.
    Kuwahara T, Asanami S, Kubo S (1998) Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells. Nutrition 14(6):496–501. CrossRefPubMedGoogle Scholar
  25. 25.
    Ghai B, Makkar JK, Bala I, Wig J (2010) Effect of parecoxib pretreatment and venous occlusion on propofol injection pain: a prospective, randomized, double-blinded, placebo-controlled study. J Clin Anesth 22(2):88–92. CrossRefPubMedGoogle Scholar
  26. 26.
    Nagao S, Furihata M, Fukagawa K, Furihata T, Matsuhashi Y, Wada T (2017) Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. J Infect Chemother 23(7):493–497. CrossRefPubMedGoogle Scholar
  27. 27.
    Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080. CrossRefPubMedGoogle Scholar
  28. 28.
    Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117(16):2104–2113. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yusuke Suwa
    • 1
    Email author
  • Jun Watanabe
    • 2
  • Mitsuyoshi Ota
    • 2
  • Shinsuke Suzuki
    • 1
  • Hirokazu Suwa
    • 3
  • Kazuteru Watanabe
    • 4
  • Shuji Saito
    • 5
  • Koutaro Nagamine
    • 6
  • Masashi Momiyama
    • 4
  • Atsushi Ishibe
    • 1
  • Yusuke Saigusa
    • 7
  • Takeharu Yamanaka
    • 7
  • Itaru Endo
    • 1
  1. 1.Department of Gastroenterological SurgeryYokohama City University Graduate School of MedicineYokohamaJapan
  2. 2.Gastroenterological CenterYokohama City University Medical CenterYokohamaJapan
  3. 3.Department of SurgeryYokosuka Kyosai HospitalYokosukaJapan
  4. 4.Department of SurgeryNTT Medical Center TokyoTokyoJapan
  5. 5.Department of SurgeryNational Hospital Organization Yokohama Medical CenterYokohamaJapan
  6. 6.Department of SurgeryYokosuka Municipal Citizen’s HospitalYokosukaJapan
  7. 7.Department of BiostatisticsYokohama City UniversityYokohamaJapan

Personalised recommendations